Overview

The Florida Department of Children and Families (DCF) Overdose Prevention Program (OPP) is designed to reduce opioid overdose deaths by providing access to FDA-approved emergency opioid antagonists (naloxone), as defined in s. 381.887(1)(d), F.S., to organizations that serve individuals at risk of witnessing or experiencing an opioid overdose. NARCAN Nasal Spray is the naloxone product DCF currently purchases and makes available to eligible organizations. The OPP has 2 primary goals:

1. Provide overdose recognition and response training to organizations and individuals who may witness or experience an overdose; and
2. Distribute free naloxone kits to individuals at risk of experiencing an opioid overdose, as well as to friends and family members who may witness an overdose.

Eligibility

Eligible organizations include:
- Non-profit organizations (regardless of contract with one of the Department’s Managing Entities)
- For-profit organizations that have an existing contract with one of the Department’s Managing Entities
- Public and private methadone clinics (regardless of contract with one of the Department’s Managing Entities)

Restrictions

Due to limited funding, DCF naloxone kits are not to be handed out to law enforcement departments, EMS agencies, or fire departments. However, if EMS agencies or fire departments want to start a naloxone “leave behind” program, where free naloxone kits would be left at the scene of an overdose with the person who overdosed and/or loved ones, they are eligible to receive DCF naloxone for this purpose.

Requirements

Organizations receiving naloxone kits from the Department must:
- Receive overdose prevention training from the Department prior to distributing naloxone.
- Identify a pharmacy licensed in the State of Florida to receive shipments of naloxone from Florida State Hospital.
- Distribute take-home naloxone kits, free of charge, to individuals at risk of experiencing an overdose, and/or to family members, friends, caregivers who may witness an overdose, along with the proper education to use the medication.
- Submit monthly naloxone distribution reports.
**Placing an Order**

Organizations interested in receiving naloxone must submit all completed documentation via email to DCF’s Overdose Prevention Coordinator. It is the responsibility of the organization to submit updated/renewed documents as needed. Required documentation includes:

1. Pharmacy license for the pharmacy that will be receiving naloxone shipments
2. Signature Authorization (Appendix A)
3. NARCAN Order Form (Appendix B)
4. Naloxone distribution plan OR signed Naloxone Distribution Standing Order (Appendix D)

**Data Collection and Reporting**

Organizations must complete the “DCF NARCAN Distribution Monthly Report” (Appendix C) and submit reports via email to DCF’s Overdose Prevention Coordinator on a monthly basis.

Reports are due by the 15th of each month to reflect the distribution activities of the previous month. For example, a report for the month of May is due by June 15th and will reflect NARCAN distribution activities from May 1 – 31.

**Sample Policies**

The organization may need to operate under a non-patient specific naloxone standing order, authorized by a licensed prescriber, to hand out naloxone kits directly to individuals at risk of witnessing or experiencing an opioid overdose. A sample non-patient specific naloxone standing order for organizations is attached as Appendix D. Please review with your organization to determine if this policy is needed.

**DCF Contact Information**

Name: Amanda Muller  
Title: Overdose Prevention Coordinator  
Phone: 850-717-4431  
Email: Amanda.Muller@myFLfamilies.com
SIGNATURE AUTHORIZATION FORM

Signature Authorization
NARCAN Program
Florida State Hospital

Please list the individuals at your organization authorized to place orders for NARCAN.

<table>
<thead>
<tr>
<th>Name</th>
<th>Facility</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SIGNATURE OF APPROVAL: _____________________
TITLE: _____________________
DATE _____________________

(Needs to be approved by supervisor of highest-level employee listed above)

Florida State Hospital
100 North Main Street/POB 1000 • Chattahoochee, Florida 32324-1000
Mission: Work in partnership with local communities to protect the vulnerable, promote strong and economically self-sufficient families, and advance personal and family recovery and resiliency

If you require Americans with Disabilities Act accommodations to participate in an event at Florida State Hospital, please notify Human Resources at (850) 663-7585 at least seven (7) days prior to the event. Deaf or hard of hearing individuals may call 1-800-955-8771.

2012 F ACCREDITED
GOVERNOR’S STERLING AWARD RECIPIENT
APPENDIX B

NARCAN Order Form

Complete the sections highlighted in yellow. In the box under “Quantity” write the number of NARCAN kits being requested. Email completed order forms to Amanda.Muller@myFLfamilies.com

---

**SUPPLY INVENTORY MANAGEMENT SYSTEM**

Supply Requisition

<table>
<thead>
<tr>
<th>Action Code</th>
<th>Sub Code</th>
<th>Organization Code</th>
<th>Expiration Date</th>
<th>Other Code</th>
<th>Quantity</th>
<th>Unit Price</th>
<th>Total Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 0 4 3 0 4 6 4 4 0 8</td>
<td>N C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Pharmacy Address:**

<table>
<thead>
<tr>
<th>Stock Number</th>
<th>Quantity</th>
<th>Unit Price</th>
<th>Total Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 5 0 5 0 0 5 2 3 7 3 2</td>
<td></td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
</tbody>
</table>

**Filled By**

<table>
<thead>
<tr>
<th>Date</th>
<th>Received By</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Requestor’s Telephone Number (SubCom, if available)**

| Date | |
|------||

---
APPENDIX C
DCF NARCAN Distribution Monthly Report

NARCAN distribution reports are due by the 15th of each month to reflect the distribution activities of the previous month. For example, a report for the month of May is due by June 15th and will reflect NARCAN distribution activities from May 1 – 31.

Email completed monthly reports to Amanda.Muller@myFLfamilies.com

Reporting Period Month and Year:

Organization Name:

Point of Contact:

Email:

Phone:

<table>
<thead>
<tr>
<th>Number of NARCAN Kits Distributed</th>
<th>Number of Overdose Reversals Reported to Organization</th>
<th>Number of Overdose Reversals that occurred on-Site (bathroom, parking lot, etc.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date:</td>
<td>This month:</td>
<td>This month:</td>
</tr>
<tr>
<td>Total to Date:</td>
<td>Total to Date:</td>
<td>Total to Date:</td>
</tr>
</tbody>
</table>

Please provide additional notes, comments, success stories, or feedback in the box below.
Naloxone hydrochloride is indicated for the reversal of opioid overdose induced by natural or synthetic opioids in the setting of respiratory depression or unresponsiveness. It is contraindicated in patients known to be hypersensitive to naloxone hydrochloride. Naloxone is not a substitute for emergency medical care. Naloxone only lasts for 30-90 minutes. After naloxone administration, a person may relapse into respiratory depression once the medication wears off – always get help immediately. The use of naloxone may result in symptoms of acute opioid withdrawal. This non-patient specific naloxone standing order will be reviewed carefully against the most current recommendations and may be revised by the authorized prescriber. This non-patient specific naloxone standing order covers the possession and distribution of naloxone kits, to include naloxone hydrochloride, intranasal device, and overdose prevention educational materials, in conjunction with the Overdose Prevention and Education Program and in compliance with Chapter 381.887, Florida Statutes.

1. This non-patient specific naloxone standing order authorizes [ORGANIZATION NAME] Overdose Prevention and Education Program, including [ORGANIZATION NAME] employees and volunteers, to pick up supplies of naloxone kits from a pharmacy licensed in the State of Florida and to maintain supplies of naloxone kits for the purpose of distributing kits to a person at risk of experiencing an opioid-related overdose or to a family member, friend, or other person in a position to assist a person at risk of experiencing an opioid-related overdose.

2. Prior to distributing naloxone, employees and volunteers of [ORGANIZATION NAME] shall train individuals on the proper use of the medication. The training shall include, at a minimum:
   - Recognition of a possible opioid overdose
• Assessment with sternal rub
• Action – call 911 and administer naloxone
• Naloxone onset (2 – 3 minutes), duration (30 – 90 minutes), and side effects (withdrawal)

3. Maintenance of supplies: Naloxone will be stored at room temperature between 59°F to 77°F (15°C to 25°C) in a secure location. Naloxone may be stored for short periods between 39°F to 104°F (4°C to 40°C). Expiration dates will be checked prior to distribution. Records will be maintained on the inventory of naloxone kits.

4. Reporting: Monthly reports of naloxone distribution and overdose reversals will be submitted via email to DCF’s Overdose Prevention Coordinator at Amanda.Muller@myFLfamilies.com.

**Persons to Receive Naloxone Kits**
- Persons who use illicit opioids (heroin, fentanyl, etc.)
- Persons who engage in nonmedical opioid use
- Persons who are experiencing or at risk of homelessness
- Persons with a history of opioid intoxication or overdose and/or recipients of emergency medical care for acute opioid poisoning
- Persons with an opioid prescription
- Persons released from correctional facilities
- Persons with an opioid prescription who also suffer from renal dysfunction, hepatic disease, cardiac disease, or HIV/AIDS

**Persons to Receive Naloxone Kits (continued)**
- Persons entering, enrolled, or being discharged from opioid detoxification and abstinence-based substance abuse treatment programs
- Persons entering, enrolled, or being discharged from medication assisted treatment programs for opioid use disorder or pain management
- Persons who are on a waitlist or call-back list to receive substance abuse treatment services for opioid use
- Persons who may have difficulty accessing emergency medical services
- Persons who request naloxone
- Family members, friends, caregivers, or other individuals who know someone that meets any of the above criteria and may be a witness to an opioid overdose

**Order to Distribute**

Upon satisfactory assessment that the person to receive the naloxone kit is a person at risk of experiencing an opioid-related overdose or a family member, friend, or other person in a position to assist a person at risk of experiencing an opioid-related overdose, and upon completion of training regarding recognizing and responding to suspected opioid overdose, distribute naloxone kit(s), to include at a minimum:
- Two devices of NARCAN® Nasal Spray
- Printed materials regarding overdose prevention and treatment, to include information regarding recognizing and responding to suspected opioid overdose and the importance of summoning emergency responders

**Directions for Administration**
Administer NARCAN Nasal Spray to a person suspected of an opioid overdose with respiratory depression or unresponsiveness as follows:

1. Activate emergency medical services / call 911
2. If indicated, initiate rescue breathing
3. Push the middle portion of the NARCAN Nasal Spray device to spray 4mg of naloxone into one nostril
4. Continue rescue breathing and monitor respiration and responsiveness of NARCAN recipient
5. If no response after 2-3 minutes, administer the second dose of NARCAN Nasal Spray into the alternate nostril, and repeat Step 4
6. When emergency medical services arrive, inform personnel that NARCAN has been administered to the individual.

* Organizations should edit the “Persons to Receive Naloxone Kits” section to reflect who they will be distributing naloxone to – this is a sample policy.